supported by an independent educational grant from · 2019-09-19 · patients with advanced biliary...
TRANSCRIPT
Supported by an Independent Educational Grant from
MEETING SUMMARY
AASLD 2016, BOSTON USANOVEMBER 11TH TO 15TH 2016
DR. MOHAMED BOUATTOUR
HÔPITAL UNIVERSITAIRE BEAUJON, PARIS, FRANCE
NON-HCC HEPATIC MALIGNANCIES
T RA N S L AT I N G T H E A B C- 0 2 T R I A L I N TO DA I LY P RACT I C E : O U TCO M E O F PA L L I AT I V E T R E AT M E N T I N PAT I E N T S W I T H A DVA N C E D B I L I A RY T RACT CA N C E R
T R E AT E D W I T H G E M C I TA B I N E A N D C I S P L AT I N
MARCIA GASPERSZ ET AL
Centers: Rotterdam, Amsterdam, Zwolle, Breda, Hoorn, Den Bosch, Arnhem, Nijmegen, Hilversum,
Alkmaar, Apeldoorn (NETHERLANDS)
4* Valle J. et al. New Eng J Med 2010
AIMS
Gemcitabine and cisplatin is the standard of care in patients with advanced biliary tract cancer based on the ABC-02 trial*
To evaluate this chemotherapy regimen in clinical practice
5* PS: performance status, GFR: Glomerular filtration rate
METHODS
2010-2015
208 patients included
Inclusion criteria ABC-02 trial
PS: 0-2
Bilirubin ≤ 1.5 ULN
AST/ALT ≤ 5 ULN
Creatinin ≤ 1.5 ULN and GFR ≥ 45 ml/min
Group 1N = 71
Group 2N = 61
Group 3N = 65
• Patients received chemotherapy
• Met the criteria of the ABC-02 trial
• Patients received chemotherapy
• Did not meet the criteria of ABC-02 trial
Best supportive care without
chemotherapy
6
MAIN RESULTS
Overall survival Progression free survivalGroup 1 = 9.7 months (95%CI: 7.1 -12.3 ) Group 2 = 9.4 months (95%CI: 7.2 - 11.6 ) Group 3 = 7.6 months (95%CI: 5.0 -10.2 ) p = 0.729 (group 1 versus 2) p = 0.011 (group 1 and 2 versus 3 )
Group 1 = 6.0 months (95%CI: 4.6- 7.4) Group 2 = 4.6 months (95%CI: 3.3- 5.9) (p=0.789)
Toxicities were similar between Groups 1 and 2
7
CONCLUSION
First line treatment with gemcitabin and cisplatin appearssafe and efficient in routine use for patients with advancedbiliary tract cancer
SURVEILLANCE FOR HEPATOBILIARY CANCER IN PRIMARY SCLEROSING
CHOLANGITIS
NAVINE NASSER-GHODSI ET AL
Centers: Phoenix Amarillo, Rochester, Sacramento, Philadelphia, UNITED STATES
9
AIM
The utility of surveillance program by imaging in patients with Primary Sclerosing Cholangitis (PSC) to detect biliary tract cancer and its impact on the outcome
10
METHODS
1992-2012
Surveillance program: annual imaging (US, CT, or MR)
serum CA 19-9
Diagnosis of biliary tract cancer histopathologically confirmed
11
MAIN RESULTS
Biliary tract cancer (n=31)
Surveillance program group
(n=9)
No surveillance program group
(n=22)
Surveillance group No surveillance group p
5-year survival rate 65% 51% 0.5
Cancer-related deaths 33% 41% 0.5
Liver transplantation 67% 55% 0.42
Patients with PSC (n=763)
12
CONCLUSION
Surveillance program in PSC patients seems to have a positive impact on outcome of patients
Larger studies are needed to confirm these results
A COMPARISON OF PROGNOSTIC SCHEMES FOR PERIHILARCHOLANGIOCARCINOMA
STEFAN BUETTNER ET AL
Centers: Rotterdam, NETHERLANDS – Baltimore, Atlanta, Stanford, Nashville, Missouri, Madison, Louisville Winston-Salem, Columbus, New York,
UNITED STATES - Verona, ITALY
14* American Joint Committee on Cancer: AJCC
AIMS
Limitation of the AJCC* staging system for perihilarcholangiocarcinoma (PHC)
Validation of a proposed nomogram
15
METHODS
1998-2014
407 patients resected for PHC
16
MAIN RESULTS (1)
Nomogram based on: age, lymphovascular invasion, perineural invasion and lymph node metastases
42.2
55.6
45.9
57.963.1
70.8
45.7
57.1
0
10
20
30
40
50
60
70
80
3 year mortality 5 year mortality
Stage I Stage II Stage III Stage IV
Proposed nomogram Overall survival by AJCC stage
17
MAIN RESULTS (2)
Nomogram based on: age, lymphovascular invasion, perineural invasion and lymph node metastases
18.824.8
51
65.763.7
77.676.5
83.4
0
10
20
30
40
50
60
70
80
90
3 year mortality 5 year mortality
Stage I Stage II Stage III Stage IV
Proposed nomogram Overall survival by proposed nomogram stage
C-Index AJCC 0.570Proposed nomogram 0.682
18
CONCLUSION
This nomogram seems to better predict survival than the AJCC staging system in patients with PHC
It might be a more useful tool for clinical decision-making and prognostic stratification
Dr. Antoine Lacombe Pharm D, MBAPhone: +41 79 529 42 [email protected]
HCC CONNECTBodenackerstrasse 174103 Bottmingen SWITZERLAND
Dr. Froukje SosefMDPhone: +31 6 2324 [email protected]